Trials / Completed
CompletedNCT02855255
Study Comparing Two Stop Smoking Intervention Efficacies
Comparing the 26 Week Efficacy of Allen Carr's Easyway to Stop Smoking and NHS 1-1 Counselling Provision
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 620 (actual)
- Sponsor
- London South Bank University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The proposed study will compare the efficacy of two psychological stop smoking interventions.
Detailed description
The proposed study comprises a randomised controlled trial (n = 620) which will compare the efficacy of two psychological stop smoking interventions. Specifically, Allen Carr's Easyway smoking cessation programme comprising one 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) and a 1-1 counselling service available via the NHS (comprising one 30 minute session and four weekly follow ups of 10-15 minutes) will be compared. The efficacy of both treatments will be followed up at 4, 12 and 26 weeks after treatment. The evaluation will be compliant with the Russell 6 Standard (which requires, amongst other things, a double blind, randomised design, chemical verification of quit outcomes, and the inclusion of all participants who received treatment in the final analysis). The findings will add to the evidence base around the use of the Allen Carr method, in particular by testing it in non-commercial settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | NHS 1-1 smoking cessation programme. | Smoking cessation using cognitive behavioural therapy/motivational interviewing |
| BEHAVIORAL | Group smoking cessation programme | Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form. |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2018-05-25
- Completion
- 2018-05-25
- First posted
- 2016-08-04
- Last updated
- 2019-03-25
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02855255. Inclusion in this directory is not an endorsement.